Business Wire

Aqara Announces Global Availability of Smart Lock U200

9.7.2024 10:00:00 EEST | Business Wire | Press release

Share

Aqara, a global leader and pioneer in IoT, today announced the official launch of the highly anticipated Smart Lock U200. Designed as a retrofit, keyless solution for home access management, the U200 lock offers unparalleled convenience, advanced security features, and seamless interoperability across smart home ecosystems and devices thanks to its native Matter compatibility.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240709404547/en/

Aqara Smart Lock U200 (Photo: Business Wire)

The Aqara Smart Lock U200 brings a modern keyless lifestyle to a broad array of homeowners and renters, and provides multiple secure door entry options, including Apple home keys, which allow iOS users to unlock effortlessly by tapping a compatible iPhone or Apple Watch. The U200 distinguishes itself as one of the first Matter-over-Thread locks to support home key unlocking and is also one of the first retrofit smart locks to feature Apple home key.

Other unlocking methods of the Smart Lock U200 include:

  • Fingerprint recognition: Fast and secure access with the high-precision fingerprint reader.
  • PIN codes: Personalized codes can be entered on the included, pre-paired wireless keypad. Moreover, Aqara Home users can manage guess access easily with not only periodic passwords but also one-time passwords that can be remotely created, shared, and used even when the lock is disconnected from any platforms.
  • Mobile apps and voice assistants: Remote control via Aqara Home, Alexa, Apple Home/Siri, Google Home/Google Assistant, SmartThings, Home Assistant, and more1.
  • Aqara NFC cards: Quick and easy unlocking using Aqara’s NFC key fobs2.
  • Traditional keys: emergency access with the original keys.

The U200 lock stands out with its hassle-free retrofit design, allowing homeowners and renters to upgrade their existing locks - such as Euro mortise locks and US deadbolt locks - without the need to change keys or modify the door structure. This lock provides an instant smart update to most homes and is suitable for DIY installation, as attaching the U200 over the existing lock is simple and requires no tool apart from a screwdriver.

Security is a top priority with the Smart Lock U200. It features advanced encryption to protect against hacking, a tamper alarm on the wireless keypad, and an auto-lock function that secures the door automatically after a set period. Additionally, the U200 provides real-time notifications to keep users informed about their home’s security status.

The U200 retains many popular features of the previous Aqara locks, such as local and encrypted storage of sensitive data like fingerprints and passwords, anti-peep PIN code protection, Do-Not-Disturb mode, Passage mode, and Night Latch mode3. Furthermore, it adds thoughtful features like quiet unlock mode to minimize the noise level, pull spring feature for handle-less or inward-opening doors, as well as turn-to-lock and turn-to-unlock functions.

Built upon the energy-efficient Thread protocol, the U200 lock is designed for extended use. The lock runs on rechargeable Li-Ion batteries and boasts a battery life of up to 6 months between each charge. Additionally, the IPX5-rated wireless keypad is operable with AAA batteries or existing doorbell wiring, which allows for uninterrupted usage4.

The Smart Lock U200 is now available at Aqara’s Amazon brand stores throughout North America (US, Canada) and Europe (France, Germany, Italy, Netherlands, Poland, Spain, UK), as well as through select Aqara retailers worldwide.

The U200 lock is compatible with Euro mortise locks with Emergency Function, and supports various cylinders including EU profile cylinders, select Scandi profile cylinders and UK oval cylinders. An Emergency Function enables the cylinder to be unlocked from the outside using a key, even if another key is already inserted on the inside. Adjustable cylinders are sold separately by Aqara. The U200 is also compatible with single-cylinder deadbolt locks.

For more information on the U200 lock and its compatibility, please visit our website.

  1. A Matter controller with Thread Border Router functionality is required to connect the Smart Lock U200 to any third-party Matter-enabled system.
  2. Aqara NFC card is available in-box with the Smart Lock U200 Kit or sold separately.
  3. Some of these features may not be available at the time of launch, and will be added via subsequent OTA updates.
  4. The 6-month battery life is based on the assumption of 8 cycles of unlocking and locking per day. To operate the wireless keypad with the existing doorbell wiring, a 12V-24V AC/DC power supply is required.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240709404547/en/

Contacts

For Media Inquiries:
media@aqara.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye